Drugs
FDA appears to be sustaining — and in some cases accelerating — its scrutiny of prescription drug advertising months after launching a high-profile enforcement push in 9/2025. The September initiative included 65 Warning and untitled letters issued the same day to biopharmaceutical manufacturers. In the months since, CDER Office of
Drugs
FDA has placed a partial clinical hold on a MacroGenics Phase 2 (LINNET) trial of its investigational immunotherapy lorigerlimab, halting enrollment of new patients while allowing those already in the study to continue treatment. MacroGenics says the agency action followed the company’s recent decision to temporarily pause enrollment after
Drugs
Trump 2.0 appears to be changing the FDA approval landscape, and new opportunities and pitfalls abound for defendants seeking to establish a preemption defense. That’s the view of attorney Grant Hollingsworth (Hollingsworth) writing in an online post. Hollingsworth says there are already regulatory pilot programs and deregulatory initiatives
Drugs
FDA has cited significant data integrity and quality control failures at an Indian manufacturing facility operated by Aurobindo Pharma, raising concerns about the reliability of testing records and the oversight of drugs distributed to the U.S. market. The findings, detailed in a just-posted Form FDA 483, follow a
Drugs
FDA has accepted for review a Genentech NDA for giredestrant, setting up a potential new treatment option for patients with endocrine-resistant breast cancer later this year. The company says it is seeking approval for the therapy’s use in combination with everolimus for adults with estrogen receptor (ER)-positive,
Drugs
A Maryland federal judge has dismissed a physician’s bid to force FDA to create a special, conditional access pathway for certain experimental Alzheimer’s treatments, holding that the doctor lacked standing to sue. Maryland physician Jianyi Zhang sued FDA “on behalf of millions of individuals” with Alzheimer’s disease
Drugs
FDA has accepted for priority review a Savara BLA for Molbreevi as a treatment for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The agency has set a user fee review action date of 8/22. Autoimmune PAP is described as a rare and potentially serious lung disease marked by the accumulation
Drugs
CDER acting director Tracy Beth Hoeg is preparing new safety reviews of widely used antidepressants and monoclonal antibodies for respiratory syncytial virus (RSV), setting up fresh tensions with major medical societies and manufacturers over products many clinicians consider well established. In her first address to staff as acting director, Hoeg
Drugs
Hyloris Pharmaceuticals says a recent FDA inspection of its Greek manufacturing partner resulted in an “Official Action Indicated” designation that could delay approval of its proposed valacyclovir oral suspension product in the U.S. Hyloris says its NDA remains under FDA review, despite a previously assigned review action target date
Drugs
FDA has released the 19-page form FDA-483 with seven observations, including one repeated observation, from an 11/10-11/25/2025 inspection at the Lupin drug manufacturing facility in Verna, Salcette, Goa, India. The specific inspection observations were: * failure to fully follow the responsibilities and procedures applicable to
Drugs
FDA has granted Pilatus Biosciences a fast-track designation for its lead drug candidate, PLT012, for treating hepatocellular carcinoma (HCC). PLT012 is described as a first-in-class monoclonal antibody designed to inhibit CD36, a lipid transporter implicated in metabolic immune suppression within the tumor microenvironment. CD36 is expressed on
Drugs
At a 1/21 GDUFA 4 reauthorization negotiating session, industry representatives offered counterproposals and responses on several topics raised by FDA in previous sessions. Meeting minutes indicate that: * Industry responded to FDA’s counter proposal on invoice timing and indicated FDA’s position would be acceptable, provided the agency ensures
Drugs
A 5/12-5/16/2025 FDA Bioresearch Monitoring Program inspection at the clinical trial site maintained by Dr. Bertrand Cole in Portsmouth, NH, found objectionable conditions in two clinical investigations. A 2/2 Warning Letter says Cole failed to ensure that the investigation was conducted according to the investigational
Drugs
The Sedgwick Recall Index says there were 978 medical device recalls in 2025 involving 490.23 million units. The report says that was fewer recalls but more units than in 2024 (1,059 events and 440.41 million units). The total number of recalled units in 2025 was the highest
Drugs
A newly published FDA perspective in the New England Journal of Medicine outlines a significant shift in how the agency intends to evaluate new drug applications: moving from a longstanding default expectation of two pivotal trials to one. In the article, FDA commissioner Marty Makary and CBER director Vinay Prasad
Drugs
Eli Lilly is reporting that combining its psoriasis biologic Taltz (ixekizumab) with obesity drug Zepbound (tirzepatide) led to significantly greater skin clearance and weight loss than Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or who are overweight. Topline results from the 52-week Phase 3b
Drugs
FDA has accepted and will review the Hansa Biopharma BLA for imlifidase, which has been conditionally approved as Idefirix in several other jurisdictions for the desensitization treatment of highly sensitized adult kidney transplant patients. A company statement says imlifidase is a unique IgG-cleaving enzyme that rapidly inactivates more than
Drugs
FDA commissioner Marty Makary says the agency will step up enforcement against unlawful mass compounding of GLP-1 weight-loss drugs, pursue an aggressive agenda to move more medicines over the counter, and accelerate early-stage clinical trials in the U.S. Speaking to CNBC at a policy event in
Drugs
Three Hyman, Phelps & McNamara attorneys mark Rare Disease Month by expressing their desire for a future in which regulatory flexibility is applied consistently when appropriate. Writing in their firm’s FDA Law Blog, the attorneys say that while the agency’s Rare Disease Innovation Hub aims to “enhance and
Drugs
Having operated since its Fall 2024 inception with no dedicated budget and only the director as a full-time staff member, the FDA Rare Disease Innovation Hub is poised to move forward in 2026 with $1 million in funds from CBER and CDER and a small dedicated staff. The Hub
Drugs
FDA has accepted for priority review a Bristol Myers Squibb NDA for iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma. If approved, iberdomide would become the first therapy in a new class of medicines known as cereblon E3 ligase modulators, or CELMoD agents.
Drugs
A 3/31-4/8/2025 FDA inspection at the Cosmetic Manufacturers ' drug manufacturing facility in Helensvale, Queensland, Australia, found significant violations of current good manufacturing practice (CGMP) regulations for finished drugs. A 2/6 Warning Letter says the specific violations were: * failure to have, for each batch of